Economic information and modeling report
Modeling overview
1 evidence topic · 2 sources
Summary
The economic evidence in this report concerns broader mitochondrial disease populations rather than a budget impact model for SL1009. A U.S. claims study reported per member per month costs of $4,829 for pediatric participants and $3,100 for adults. An Australian study estimated annual average household costs of AU$112,721, with 92% attributable to societal costs. These estimates describe disease burden, not SL1009 acquisition costs, treatment-related cost offsets, or incremental budget impact. The report contains no SL1009-specific budget impact model.